Other
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Roivant Sciences Cash Provided by (Used in) Financing Activity, Including Discontinued Operation increased by 274.8% to $328.19M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 220.2%, from -$272.95M to $328.19M. Over 3 years (FY 2021 to FY 2024), Cash Provided by (Used in) Financing Activity, Including Discontinued Operation shows a downward trend with a 57.0% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityVolatile
First reportedQ1 2020
Last reportedQ3 2025Feb 6, 2026
How to read this metric
Negative values often indicate significant share buybacks or debt repayment, while positive values suggest new capital raising or increased borrowing.
Detailed definition
The total net cash flow resulting from all financing activities, including proceeds from debt issuance, share repurchase...
Peer comparison
Standard line item in the Statement of Cash Flows for all public companies.
Metric ID:
other_net_cash_provided_by_used_in_financing_activitiesHistorical Data
18 periods
| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.21M | $303.93M | $0.00 | $1.07M | $141.98M | $0.00 | $154.50M | $210.33M | $7.48M | $207.87M | $236.64M | $0.00 | -$660.62M | -$109.07M | -$272.95M | -$177.15M | -$187.77M | $328.19M |
| QoQ Change | — | >999% | -100.0% | — | >999% | -100.0% | — | +36.1% | -96.4% | >999% | +13.8% | -100.0% | — | +83.5% | -150.2% | +35.1% | -6.0% | +274.8% |
| YoY Change | — | — | — | — | >999% | -100.0% | — | >999% | -94.7% | — | +53.2% | -100.0% | <-999% | -152.5% | -215.3% | — | +71.6% | +220.2% |
Range-$660.62M – $328.19M
CAGR+126.3%
Avg YoY Growth>999%
Median YoY Growth-94.7%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at Other Companies
Frequently Asked Questions
- What is Roivant Sciences's cash provided by (used in) financing activity, including discontinued operation?
- Roivant Sciences (ROIV) reported cash provided by (used in) financing activity, including discontinued operation of $328.19M in Q4 2025.
- How has Roivant Sciences's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
- Roivant Sciences's cash provided by (used in) financing activity, including discontinued operation increased by 220.2% year-over-year, from -$272.95M to $328.19M.
- What is the long-term trend for Roivant Sciences's cash provided by (used in) financing activity, including discontinued operation?
- Over 3 years (2021 to 2024), Roivant Sciences's cash provided by (used in) financing activity, including discontinued operation has grown at a 57.0% compound annual growth rate (CAGR), from $315.21M to -$1.22B.
- What does cash provided by (used in) financing activity, including discontinued operation mean?
- The net change in cash resulting from all financing-related activities.